• 1. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indolizidines Indolizidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indolizidines

Isomitraphylline (CAS No. 4963-01-3): A Comprehensive Overview of Its Chemical Profile and Emerging Applications

Isomitraphylline, with the chemical identifier CAS No. 4963-01-3, is a compound that has garnered significant attention in the field of pharmaceutical chemistry and biochemistry due to its unique structural properties and potential therapeutic applications. This introduction aims to provide a detailed exploration of Isomitraphylline, delving into its chemical structure, pharmacological effects, and the latest research findings that underscore its significance in modern medicine.

The molecular formula of Isomitraphylline is C₂₁H₂₈N₂O₂, reflecting its complex organic composition. This compound belongs to the class of xanthine derivatives, which are well-known for their role in various pharmacological contexts. The structural framework of Isomitraphylline incorporates a purine core, which is a hallmark of many bioactive molecules involved in cellular signaling and metabolic processes.

In recent years, Isomitraphylline has been studied extensively for its potential in modulating inflammatory responses and cardiovascular functions. Research indicates that this compound exhibits anti-inflammatory properties by inhibiting key enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). These enzymes are pivotal in the production of prostaglandins and leukotrienes, which are mediators of inflammation. By targeting these pathways, Isomitraphylline demonstrates promise in conditions characterized by excessive inflammation, such as rheumatoid arthritis and inflammatory bowel disease.

Beyond its anti-inflammatory effects, Isomitraphylline has shown remarkable potential in cardiovascular applications. Studies have highlighted its ability to enhance endothelial function, which is crucial for maintaining vascular health. The compound appears to promote the production of nitric oxide (NO), a vasodilator that helps relax blood vessels and improve blood flow. This mechanism is particularly relevant in the context of cardiovascular diseases such as hypertension and atherosclerosis.

The pharmacokinetic profile of Isomitraphylline is another area of interest. Upon administration, it exhibits moderate solubility in water and oil, facilitating its absorption through both oral and intravenous routes. Its half-life in the bloodstream is approximately 6 hours, suggesting a reasonable balance between efficacy and duration of action. Additionally, preliminary studies indicate that Isomitraphylline is metabolized primarily through the cytochrome P450 enzyme system, which has implications for drug-drug interactions.

Emerging research also explores the neuroprotective potential of Isomitraphylline. Preclinical studies have demonstrated that this compound can mitigate neuroinflammation and oxidative stress, two key pathological features associated with neurodegenerative diseases such as Alzheimer's and Parkinson's. The ability of Isomitraphylline to cross the blood-brain barrier further enhances its therapeutic relevance in neurological disorders.

The synthesis of Isomitraphylline involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Advanced synthetic methodologies, including catalytic hydrogenation and nucleophilic substitution, have been employed to optimize the production process. These techniques not only improve efficiency but also minimize unwanted byproducts, making the synthesis more sustainable.

In conclusion, Isomitraphylline (CAS No. 4963-01-3) represents a compelling compound with diverse pharmacological applications. Its ability to modulate inflammatory pathways, enhance cardiovascular health, and protect against neurodegenerative processes positions it as a promising candidate for further clinical development. As research continues to uncover new insights into its mechanisms of action, the therapeutic potential of this xanthine derivative is likely to expand, offering hope for innovative treatments in multiple medical fields.

• 509-80-8(Mitraphylline)
• 6877-32-3(Corynoxine)
• 3489-06-3(Spiro[3H-indole-3,6'(4'aH)-[1H]pyrano[3,4-f]- indolizine]-4'-carboxylic acid,1,2,5',5'a,7',8',10',10'a-octahydro-6- methoxy-1'-methyl-2-oxo-,methyl ester,(1'S,3S,4'aS,5'aR,10'aS)-)
• 630-94-4(Corynoxeine)
• 5629-60-7(Uncarine c)
• 76-66-4(Rhynchophylline)
• 6859-01-4(Isorhynchophylline)
• 51014-29-0(Isocorynoxeine)
• 144525-05-3(Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-aceticacid, 6'-ethyl-1,2,2',3',6',7',8',8'a-octahydro-a-(methoxymethylene)-2-oxo-, (aE,1'S,6'R,7'S,8'aS)-)
• 5171-37-9(Isopteropodine)